STOCK TITAN

Verrica Pharmaceuticals - VRCA STOCK NEWS

Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.

Verrica Pharmaceuticals Inc. (VRCA) is a clinical-stage leader in dermatology therapeutics, pioneering FDA-approved treatments for complex skin conditions. This page provides investors and healthcare professionals with essential updates on the company's advancements in medical dermatology.

Access real-time news about Verrica's clinical trials, regulatory milestones, and strategic partnerships. Our curated collection includes updates on YCANTH® (the first FDA-approved molluscum contagiosum therapy), pipeline developments like VP-315 for skin cancers, and critical business decisions affecting the dermatology sector.

Key coverage areas include FDA regulatory updates, clinical trial results, research collaborations, and market expansion strategies. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.

Bookmark this page for streamlined access to Verrica's latest developments in drug-device combination therapies and their impact on dermatological care. For comprehensive analysis of VRCA's position in medical dermatology, visit regularly for unfiltered updates directly from corporate communications and verified industry reports.

Rhea-AI Summary

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced participation of CEO Ted White in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 3:00 p.m. ET. Investors can access a live webcast of the event through the provided link or on Verrica's website, with a replay available for 30 days post-event. The company focuses on developing treatments for dermatological conditions, including its leading candidate VP-102 for molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica holds a licensing agreement with Lytix Biopharma for LTX-315.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
-
Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced the dosing of the first patient in its Phase 2 trial of LTX-315, an innovative oncolytic peptide targeting basal cell carcinoma (BCC). With 3-4 million BCC diagnoses annually in the U.S., the trial aims to provide a non-surgical treatment option, addressing a significant unmet medical need. The study will evaluate safety and efficacy in approximately 66 adult subjects. LTX-315 has shown promising immune responses in earlier trials and could potentially expand to treat squamous cell carcinoma in the future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
-
Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) reported a net loss of $9.5 million for Q4 2021, down from $13.0 million in Q4 2020. Full-year net loss was $35.1 million or $1.30 per share, compared to $42.7 million or $1.71 per share in 2020. The company recognized $12 million in license revenues for 2021. Research and development expenses rose to $3.4 million in Q4 2021, mainly due to increased manufacturing costs. Upcoming milestones include a PDUFA date of May 24, 2022, for VP-102 and a Phase 2 trial for LTX-315 in basal cell carcinoma set to begin in early 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
Rhea-AI Summary

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that President and CEO Ted White will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on March 9, 2022, at 11:10 a.m. ET. The event will be accessible via a live webcast, and a replay will be available for 30 days post-event. Verrica focuses on developing dermatology therapeutics, including its late-stage product candidate, VP-102, aimed at treating molluscum and common warts, and VP-103 for plantar warts. The company has also licensed LTX-315 for dermatologic oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced that the FDA accepted its resubmitted New Drug Application (NDA) for VP-102, targeting the treatment of molluscum contagiosum. The FDA granted a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2022. VP-102 aims to be the first FDA-approved treatment for this highly contagious skin disease affecting approximately six million people in the U.S., particularly children. The resubmission includes limited changes, and the company is optimistic about the demand for an effective treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
-
Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) has resubmitted the New Drug Application (NDA) for VP-102, aimed at treating molluscum contagiosum, to the FDA. This resubmission addresses deficiencies noted in the Complete Response Letter from September 2021, including inspection issues and user interface recommendations. CEO Ted White anticipates a 2-month review period, with a potential launch of VP-102 as the first FDA-approved treatment for this viral skin disease affecting six million people, primarily children, in the U.S. annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced the FDA's acceptance of its IND application for LTX-315, a novel oncolytic peptide for treating basal cell carcinoma, a prevalent form of skin cancer. The Phase 2 trial is expected to begin in Q1 2022. With over 5 million non-melanoma skin cancer diagnoses annually in the U.S., LTX-315 aims to offer a non-surgical treatment option. The drug shows promise in inducing immune responses against tumors and aims to improve patient outcomes compared to current surgical options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
none
-
Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) reported its third quarter financial results, revealing a net loss of $12.8 million, or $0.47 per share, compared to a loss of $10.5 million, or $0.42 per share, in Q3 2020. The company has received satisfactory resolution on deficiencies at a contract manufacturing organization from the FDA, allowing them to proceed with the approval process for VP-102, targeting molluscum contagiosum. Additionally, Verrica is advancing LTX-315 for basal cell carcinoma, submitting an IND, and expects to start a Phase 2 trial in early 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
-
Rhea-AI Summary

Verrica Pharmaceuticals (NASDAQ: VRCA) announced on September 20, 2021, that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for VP-102, aimed at treating molluscum contagiosum. While the FDA identified general quality deficiencies at the contract manufacturing organization, no specific manufacturing or clinical issues were cited for VP-102. The company remains optimistic about resolving these concerns within 30 business days, highlighting a significant unmet need for an FDA-approved treatment for the six million people affected in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
none
Rhea-AI Summary

Verrica Pharmaceuticals announced its Q2 2021 financial results, showing a net loss of $11.8 million, or $0.43 per share. This reflects a wider loss compared to $9.4 million in Q2 2020. The company recognized $12 million in license revenues from its agreement with Torii Pharmaceutical, with total cash and marketable securities at $90.1 million as of June 30, 2021. Verrica is preparing for a potential launch of its lead product candidate, VP-102, aimed at molluscum contagiosum, with a PDUFA goal date set for September 23, 2021, while also expanding its commercial operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
Verrica Pharmaceuticals

Nasdaq:VRCA

VRCA Rankings

VRCA Stock Data

45.02M
48.78M
43.3%
32.65%
2.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CHESTER